<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Levy ME</submitter><funding>Centers for Disease Control and Prevention</funding><funding>CDC HHS</funding><pagination>e13269</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10944689</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>18(3)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Although psychiatric disorders have been associated with reduced immune responses to other vaccines, it remains unknown whether they influence COVID-19 vaccine effectiveness (VE). This study evaluated risk of COVID-19 hospitalization and estimated mRNA VE stratified by psychiatric disorder status.&lt;h4>Methods&lt;/h4>In a retrospective cohort analysis of the VISION Network in four US states, the rate of laboratory-confirmed COVID-19-associated hospitalization between December 2021 and August 2022 was compared across psychiatric diagnoses and by monovalent mRNA COVID-19 vaccination status using Cox proportional hazards regression.&lt;h4>Results&lt;/h4>Among 2,436,999 adults, 22.1% had ≥1 psychiatric disorder. The incidence of COVID-19-associated hospitalization was higher among patients with any versus no psychiatric disorder (394 vs. 156 per 100,000 person-years, p &lt; 0.001). Any psychiatric disorder (adjusted hazard ratio [aHR], 1.27; 95% CI, 1.18-1.37) and mood (aHR, 1.25; 95% CI, 1.15-1.36), anxiety (aHR, 1.33, 95% CI, 1.22-1.45), and psychotic (aHR, 1.41; 95% CI, 1.14-1.74) disorders were each significant independent predictors of hospitalization. Among patients with any psychiatric disorder, aHRs for the association between vaccination and hospitalization were 0.35 (95% CI, 0.25-0.49) after a recent second dose, 0.08 (95% CI, 0.06-0.11) after a recent third dose, and 0.33 (95% CI, 0.17-0.66) after a recent fourth dose, compared to unvaccinated patients. Corresponding VE estimates were 65%, 92%, and 67%, respectively, and were similar among patients with no psychiatric disorder (68%, 92%, and 79%).&lt;h4>Conclusion&lt;/h4>Psychiatric disorders were associated with increased risk of COVID-19-associated hospitalization. However, mRNA vaccination provided similar protection regardless of psychiatric disorder status, highlighting its benefit for individuals with psychiatric disorders.</pubmed_abstract><journal>Influenza and other respiratory viruses</journal><pubmed_title>Risk of COVID-19 Hospitalization and Protection Associated With mRNA Vaccination Among US Adults With Psychiatric Disorders.</pubmed_title><pmcid>PMC10944689</pmcid><funding_grant_id>75D30120C07986</funding_grant_id><pubmed_authors>Miley K</pubmed_authors><pubmed_authors>Ball SW</pubmed_authors><pubmed_authors>Spark TL</pubmed_authors><pubmed_authors>Rao S</pubmed_authors><pubmed_authors>Dixon BE</pubmed_authors><pubmed_authors>Griggs EP</pubmed_authors><pubmed_authors>Link-Gelles R</pubmed_authors><pubmed_authors>Embi PJ</pubmed_authors><pubmed_authors>Naleway AL</pubmed_authors><pubmed_authors>Dascomb K</pubmed_authors><pubmed_authors>Murthy K</pubmed_authors><pubmed_authors>Irving SA</pubmed_authors><pubmed_authors>Stenehjem E</pubmed_authors><pubmed_authors>Ong TC</pubmed_authors><pubmed_authors>Bassett E</pubmed_authors><pubmed_authors>Gaglani M</pubmed_authors><pubmed_authors>Mamawala M</pubmed_authors><pubmed_authors>Raiyani C</pubmed_authors><pubmed_authors>Patel P</pubmed_authors><pubmed_authors>Najdowski M</pubmed_authors><pubmed_authors>Tenforde MW</pubmed_authors><pubmed_authors>Natarajan K</pubmed_authors><pubmed_authors>Dunne MM</pubmed_authors><pubmed_authors>Weber ZA</pubmed_authors><pubmed_authors>Ray C</pubmed_authors><pubmed_authors>Grannis SJ</pubmed_authors><pubmed_authors>Dickerson M</pubmed_authors><pubmed_authors>Liao IC</pubmed_authors><pubmed_authors>Arndorfer J</pubmed_authors><pubmed_authors>Grisel N</pubmed_authors><pubmed_authors>Barron MA</pubmed_authors><pubmed_authors>Beaton MA</pubmed_authors><pubmed_authors>Valvi NR</pubmed_authors><pubmed_authors>Fadel WF</pubmed_authors><pubmed_authors>Yang DH</pubmed_authors><pubmed_authors>Kharbanda AB</pubmed_authors><pubmed_authors>Levy ME</pubmed_authors><pubmed_authors>Klein NP</pubmed_authors><pubmed_authors>Han J</pubmed_authors><pubmed_authors>DeSilva MB</pubmed_authors></additional><is_claimable>false</is_claimable><name>Risk of COVID-19 Hospitalization and Protection Associated With mRNA Vaccination Among US Adults With Psychiatric Disorders.</name><description>&lt;h4>Background&lt;/h4>Although psychiatric disorders have been associated with reduced immune responses to other vaccines, it remains unknown whether they influence COVID-19 vaccine effectiveness (VE). This study evaluated risk of COVID-19 hospitalization and estimated mRNA VE stratified by psychiatric disorder status.&lt;h4>Methods&lt;/h4>In a retrospective cohort analysis of the VISION Network in four US states, the rate of laboratory-confirmed COVID-19-associated hospitalization between December 2021 and August 2022 was compared across psychiatric diagnoses and by monovalent mRNA COVID-19 vaccination status using Cox proportional hazards regression.&lt;h4>Results&lt;/h4>Among 2,436,999 adults, 22.1% had ≥1 psychiatric disorder. The incidence of COVID-19-associated hospitalization was higher among patients with any versus no psychiatric disorder (394 vs. 156 per 100,000 person-years, p &lt; 0.001). Any psychiatric disorder (adjusted hazard ratio [aHR], 1.27; 95% CI, 1.18-1.37) and mood (aHR, 1.25; 95% CI, 1.15-1.36), anxiety (aHR, 1.33, 95% CI, 1.22-1.45), and psychotic (aHR, 1.41; 95% CI, 1.14-1.74) disorders were each significant independent predictors of hospitalization. Among patients with any psychiatric disorder, aHRs for the association between vaccination and hospitalization were 0.35 (95% CI, 0.25-0.49) after a recent second dose, 0.08 (95% CI, 0.06-0.11) after a recent third dose, and 0.33 (95% CI, 0.17-0.66) after a recent fourth dose, compared to unvaccinated patients. Corresponding VE estimates were 65%, 92%, and 67%, respectively, and were similar among patients with no psychiatric disorder (68%, 92%, and 79%).&lt;h4>Conclusion&lt;/h4>Psychiatric disorders were associated with increased risk of COVID-19-associated hospitalization. However, mRNA vaccination provided similar protection regardless of psychiatric disorder status, highlighting its benefit for individuals with psychiatric disorders.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Mar</publication><modification>2026-06-23T03:18:38.07Z</modification><creation>2025-05-18T12:53:52.437Z</creation></dates><accession>S-EPMC10944689</accession><cross_references><pubmed>38494192</pubmed><doi>10.1111/irv.13269</doi></cross_references></HashMap>